JD Health International Gelecekteki Büyüme

Future kriter kontrolleri 3/6

JD Health International kazanç ve gelirin sırasıyla yıllık 14.6% ve 10.5% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 14.1% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 7.7% olacağı tahmin edilmektedir.

Anahtar bilgiler

14.6%

Kazanç büyüme oranı

14.1%

EPS büyüme oranı

Consumer Retailing kazanç büyümesi	28.3%
Gelir büyüme oranı	10.5%
Gelecekteki özkaynak getirisi	7.7%
Analist kapsamı	Good
Son güncelleme	25 Nov 2024

Gelecekteki son büyüme güncellemeleri

Güncelleme yok

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

SZSC:6618 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (CNY Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	72,249	3,902	7,946	7,122	17
12/31/2025	64,815	3,550	6,757	5,556	19
12/31/2024	57,716	3,109	5,220	4,557	19
6/30/2024	54,764	2,618	6,436	6,467	N/A
3/31/2024	54,147	2,380	5,490	5,536	N/A
12/31/2023	53,530	2,142	4,544	4,605	N/A
9/30/2023	53,576	1,930	3,135	4,311	N/A
6/30/2023	53,621	1,718	1,726	4,017	N/A
3/31/2023	50,179	1,049	2,679	4,961	N/A
12/31/2022	46,736	380	3,632	5,905	N/A
9/30/2022	42,003	-7	3,440	4,829	N/A
6/30/2022	37,270	-395	3,249	3,753	N/A
3/31/2022	33,976	-734	3,085	3,592	N/A
12/31/2021	30,682	-1,074	2,921	3,431	N/A
9/30/2021	27,463	-6,702	4,068	4,352	N/A
6/30/2021	24,243	-12,331	5,216	5,274	N/A
3/31/2021	21,813	-14,783	4,439	4,487	N/A
12/31/2020	19,383	-17,234	3,662	3,699	N/A
9/30/2020	17,007	-11,901	1,980	2,004	N/A
6/30/2020	14,631	-6,567	298	309	N/A
3/31/2020	12,737	-3,769	351	359	N/A
12/31/2019	10,842	-972	404	409	N/A
12/31/2018	8,169	215	185	187	N/A
12/31/2017	5,553	179	N/A	36	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 6618 'nin tahmini kazanç büyümesi (yıllık 14.6% ) tasarruf oranının ( 2.3% ) üzerindedir.

Kazançlar ve Piyasa: 6618 şirketinin kazançlarının (yıllık 14.6% ) Hong Kong pazarından (yıllık 11.6% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: 6618 şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: 6618 şirketinin gelirinin (yıllık 10.5% ) Hong Kong pazarından (yıllık 7.8% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 6618 şirketinin gelirinin (yıllık 10.5% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 6618 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 7.7 %).

JD Health International Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Recent updates

Investor sentiment deteriorates as stock falls 17%

Insufficient new directors

Now 22% overvalued after recent price rise

Investor sentiment improves as stock rises 15%

First half 2024 earnings released: EPS: CN¥0.65 (vs CN¥0.50 in 1H 2023)

JD Health International Inc. Announces Appointment of Professor George Lau as Independent Non-Executive Director

JD Health International Inc. to Report First Half, 2024 Results on Aug 15, 2024

Now 23% undervalued after recent price drop

Now 21% undervalued

Full year 2023 earnings released: EPS: CN¥0.69 (vs CN¥0.12 in FY 2022)

JD Health International Inc., Annual General Meeting, Jun 21, 2024

Investor sentiment improves as stock rises 16%

Investor sentiment deteriorates as stock falls 15%

Full year 2023 earnings released: EPS: CN¥0.69 (vs CN¥0.12 in FY 2022)

JD Health International Inc. to Report Q4, 2023 Results on Mar 20, 2024

Investor sentiment deteriorates as stock falls 16%

Investor sentiment deteriorates as stock falls 18%

First half 2023 earnings released: EPS: CN¥0.50 (vs CN¥0.072 in 1H 2022)

JD Health International Inc. to Report First Half, 2023 Results on Aug 16, 2023

Now 23% undervalued

Independent Non-Executive Director recently sold HK$108k worth of stock

JD Health International Inc. Announces Chief Financial Officer Changes

High number of new and inexperienced directors

Full year 2022 earnings released: EPS: CN¥0.12 (vs CN¥0.35 loss in FY 2021)

CEO & Executive Director recently sold HK$5.1m worth of stock

Independent Non-Executive Director recently sold HK$55k worth of stock

First half 2022 earnings released: EPS: CN¥0.07 (vs CN¥0.15 loss in 1H 2021)

JD Health International Inc. to Report First Half, 2022 Results on Aug 23, 2022

Chairman recently sold HK$195m worth of stock

Full year 2021 earnings released: CN¥0.35 loss per share (vs CN¥7.80 loss in FY 2020)

JD Health International Inc. Announces Board Changes

JD Health International Inc. (SEHK:6618) announces an Equity Buyback for HKD 3,000 million worth of its shares.

Full year 2021 earnings released: CN¥0.35 loss per share (vs CN¥7.80 loss in FY 2020)

Independent Non-Executive Director recently sold HK$61k worth of stock

Non-Executive Director Pang Zhang has left the company

First half 2021 earnings released: CN¥0.15 loss per share (vs CN¥2.49 loss in 1H 2020)

Full year 2020 earnings released: CN¥7.80 loss per share (vs CN¥0.45 loss in FY 2019)

Non-Executive Director has left the company

Independent Non-Executive Director has left the company

Full year 2020 earnings released: CN¥7.80 loss per share

JD Health International Inc. to Report Fiscal Year 2020 Results on Mar 29, 2021

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin